My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (NY:ATNM)

0.9710 -0.0790 (-7.52%)

Streaming Delayed Price Updated: 12:19 PM EDT, Jul 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

< Previous 1 2 Next >

Why Is Actinium Pharmaceuticals Stock Rising Today? ↗

December 12, 2025

The Actinium-225 (Ac-225) antibody radioconjugate demonstrated strong anti-tumor activity across multiple breast cancer models.

Via Stocktwits

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 26, 2025

Via Benzinga

Top movers in Wednesday's pre-market session ↗

March 26, 2025

The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

March 25, 2025

The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

(ATNM) - Analyzing Actinium Pharmaceuticals's Short Interest ↗

March 09, 2023

Via Benzinga

Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week ↗

March 23, 2025

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

Via Stocktwits

Which stocks are gapping on Thursday? ↗

March 20, 2025

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 25, 2024

Via Benzinga

ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q2 2024 ↗

August 06, 2024

ATNM stock results show that Actinium Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ↗

August 06, 2024

Via Benzinga

S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge ↗

August 05, 2024

Via Benzinga

Topics Stocks

Dow Tumbles 950 Points; ISM Services PMI Surges In July ↗

August 05, 2024

Via Benzinga

Topics Stocks

Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment ↗

August 05, 2024

FDA rejects Actinium Pharmaceuticals' Phase 3 SIERRA trial for Iomab-B's Biologics License Application due to inadequate support despite achieving a statistically significant primary endpoint. Actinium...

Via Benzinga

Nasdaq Tumbles 3%; Tyson Foods Earnings Top Views ↗

August 05, 2024

Via Benzinga

3 Under-$10 Biotech Stocks That Could Make You Rich ↗

July 11, 2024

Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis.

Via InvestorPlace

3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns ↗

July 02, 2024

These are the clinical-stage biotech stocks to buy, as they represent companies with an attractive product pipeline.

Via InvestorPlace

Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 ↗

June 10, 2024

These are the biotech stocks under $10 that are attractively valued and have potential catalysts in the form of positive clinical trials news

Via InvestorPlace

Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar ↗

June 07, 2024

These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials.

Via InvestorPlace

3 Cheap Biotech Stocks to Buy Now: May 2024 ↗

May 14, 2024

Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market.

Via InvestorPlace

ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q1 2024 ↗

April 29, 2024

ATNM stock results show that Actinium Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market ↗

April 25, 2024

The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.

Via Investor's Business Daily

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential ↗

April 15, 2024

With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.

Via InvestorPlace

High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment ↗

March 15, 2024

ATNM stock offers moonshot or crash-landing possibilities as Actinium Pharmaceuticals works relentlessly to advance life-changing treatments.

Via InvestorPlace

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory ↗

February 25, 2024

Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's After-Market Session ↗

February 09, 2024

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023 ↗

September 06, 2023

Via Benzinga

Actinium Pharma – Pivotal Results From Key New Drug In The Fight Against Cancer ↗

July 14, 2023

Sandesh Seth, CEO & Chairman of the Board of Actinium Pharmaceuticals (NASDAQ: ATNM), was recently a guest on Benzinga’s All-Access.

Via Benzinga

Actinium Pharma Cratered 37% Over Two Days — Here's Why, According To CEO Sandesh Seth ↗

February 24, 2023

Actinium CEO Sandesh Seth says the tumble this week had little to do with clinical data.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 ↗

February 21, 2023

Via Benzinga

What's Going On With Actinium Pharmaceuticals Stock? ↗

February 21, 2023

Actinium Pharmaceuticals Inc (AMEX:ATNM) shares are trading higher Tuesday after the company announced full data results from the pivotal Phase 3 SIERRA trial in patients with active, relapsed or...

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.